Effectiveness of Drotaverine HCL in reducing the duration of first stage of labour among nulliparous women at Federal Teaching Hospital, Abakaliki.

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR201810902005232

Enrollment

220

Registered

2018-10-11

Start date

2018-04-04

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth

Interventions

Drotaverine

Placebo

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Nullipara or primigravida Cervical dilation of 4-5cm only Consent No prior use of spasmolytics

Exclusion criteria

Exclusion criteria: Term PROM Coexisting masses Allergy to Drotaverine HCL Multipara Postdatism

Design outcomes

Primary

Measure	Time frame
Duration of first stage of labour	—

Secondary

Measure	Time frame
Pain, mode of delivery, maternal sideeffects, APGAR score at 1st and 5th minute, need for augmentation of abour	—

Countries

Nigeria

Contacts

Public ContactArinze Ikeotuonye

Senior Registrar

arinze790@gmail.com+2348038730293

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 11, 2026